{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:59:11Z","timestamp":1791950351662,"version":"4.3.4"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004761","name":"Hainan Province Natural Science Foundation","doi-asserted-by":"publisher","award":["824RC500"],"award-info":[{"award-number":["824RC500"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005693","name":"Hainan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M712153"],"award-info":[{"award-number":["2022M712153"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22567014"],"award-info":[{"award-number":["22567014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22367007"],"award-info":[{"award-number":["22367007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110044","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:21:41Z","timestamp":1780298501000},"page":"110044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Shared pathophysiology and therapeutic repurposing in Alzheimer's disease and type 2 diabetes: a critical review of convergent mechanisms and clinical challenges"],"prefix":"10.1016","volume":"180","author":[{"given":"Wenling","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roujun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110044_bb0005","doi-asserted-by":"crossref","unstructured":"2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023;19(4):1598\u20131695. doi:https:\/\/doi.org\/10.1002\/alz.13016.","DOI":"10.1002\/alz.13016"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0010","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3390\/ijms24021059","article-title":"Alzheimer\u2019s Disease-Biochemical and Psychological Background for Diagnosis and Treatment","volume":"24","author":"Beata","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110044_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101960","article-title":"Alzheimer\u2019s disease: molecular aspects and treatment opportunities using herbal drugs","volume":"88","author":"Thakral","year":"2023","journal-title":"Ageing Res. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/biom10010040","article-title":"Alzheimer\u2019s disease pharmacotherapy in relation to cholinergic system involvement","volume":"10","author":"Stanciu","year":"2019","journal-title":"Biomolecules"},{"issue":"8 Suppl","key":"10.1016\/j.bioorg.2026.110044_bb0025","first-page":"S177","article-title":"Economic burden of Alzheimer disease and managed care considerations","volume":"26","author":"Wong","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.bioorg.2026.110044_bb0030","series-title":"IDF Diabetes Atlas","author":"Magliano","year":"2021"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110044_bb0035","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/jdi.12087","article-title":"Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies","volume":"4","author":"Gudala","year":"2013","journal-title":"J Diabetes Investig."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110044_bb0040","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s12529-024-10274-6","article-title":"The effects of type 2 diabetes on cognitive performance: a review of reviews","volume":"31","author":"Sola","year":"2024","journal-title":"Int. J. Behav. Med."},{"key":"10.1016\/j.bioorg.2026.110044_bb0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.mad.2019.03.008","article-title":"Crucial players in Alzheimer\u2019s disease and diabetes mellitus: friends or foes?","volume":"181","author":"Kubis-Kubiak","year":"2019","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.bioorg.2026.110044_bb0050","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1435276","article-title":"Neurometabolic evidence supporting the hypothesis of increased incidence of type 3 diabetes mellitus in the 21st century","volume":"2019","author":"Rorbach-Dolata","year":"2019","journal-title":"Biomed. Res. Int."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110044_bb0055","doi-asserted-by":"crossref","first-page":"986","DOI":"10.2174\/1567205016666191106094356","article-title":"Common pathological mechanisms and risk factors for Alzheimer\u2019s disease and Type-2 diabetes: focus on inflammation","volume":"16","author":"Moyse","year":"2019","journal-title":"Curr. Alzheimer Res."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110044_bb0060","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1055\/s-0029-1243603","article-title":"Insulin signal transduction in normal cells and its role in carcinogenesis","volume":"118","author":"M\u00fcssig","year":"2010","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0065","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a031534","article-title":"The interdependent activation of son-of-Sevenless and Ras","volume":"9","author":"Bandaru","year":"2019","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110044_bb0070","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/embor.2010.160","article-title":"MAPK signalling in cellular metabolism: stress or wellness?","volume":"11","author":"Gehart","year":"2010","journal-title":"EMBO Rep."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0075","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/nep.13430","article-title":"Metformin inhibits TGF-beta 1-induced MCP-1 expression through BAMBI-mediated suppression of MEK\/ERK1\/2 signalling","volume":"24","author":"Liang","year":"2019","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0080","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases [published correction appears in Microbiol Mol biol rev. 2012 Jun;76(2):496]","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0085","doi-asserted-by":"crossref","DOI":"10.1007\/s13205-021-02738-3","article-title":"Role of insulin receptor substance-1 modulating PI3K\/Akt insulin signaling pathway in Alzheimer\u2019s disease","volume":"11","author":"Zheng","year":"2021","journal-title":"3 Biotech"},{"key":"10.1016\/j.bioorg.2026.110044_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.00629","article-title":"Altered insulin signaling in Alzheimer\u2019s disease brain - special emphasis on PI3K-Akt pathway","volume":"13","author":"Gabbouj","year":"2019","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0095","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.arr.2011.01.001","article-title":"Insulin-resistant brain state: the culprit in sporadic Alzheimer\u2019s disease?","volume":"10","author":"Correia","year":"2011","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bioorg.2026.110044_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2025.104005","article-title":"GSK-3\u03b2 dysregulation in aging: implications for tau pathology and Alzheimer\u2019s disease progression","volume":"133","author":"Rekha","year":"2025","journal-title":"Mol. Cell. Neurosci."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110044_bb0105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.tem.2011.12.004","article-title":"Insulin resistance in the nervous system","volume":"23","author":"Kim","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: Mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13024-021-00428-5","article-title":"Mammalian\/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration","volume":"16","author":"Querfurth","year":"2021","journal-title":"Mol. Neurodegener."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41583-022-00558-9","article-title":"Impaired insulin signalling and allostatic load in Alzheimer disease","volume":"23","author":"De Felice","year":"2022","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0125","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI57256","article-title":"An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer\u2019s disease- associated a\u03b2 oligomers","volume":"122","author":"Bomfim","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3904\/kjim.2010.25.2.119","article-title":"Molecular mechanism of insulin resistance in obesity and type 2 diabetes","volume":"25","author":"Choi","year":"2010","journal-title":"Korean J. Intern. Med."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110044_bb0135","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.tem.2017.05.002","article-title":"Update on GLUT4 vesicle traffic: a cornerstone of insulin action","volume":"28","author":"Jaldin-Fincati","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0140","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.3390\/ijms22042121","article-title":"Alterations of gut microbiota by Overnutrition impact Gluconeogenic gene expression and insulin signaling","volume":"22","author":"He","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0145","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/ars.2009.2668","article-title":"Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities","volume":"12","author":"Adibhatla","year":"2010","journal-title":"Antioxid. Redox Signal."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12264-013-1423-y","article-title":"Oxidative stress in Alzheimer\u2019s disease","volume":"30","author":"Chen","year":"2014","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.bioorg.2026.110044_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101529","article-title":"Deregulated mitochondrial microRNAs in Alzheimer\u2019s disease: focus on synapse and mitochondria","volume":"73","author":"Gowda","year":"2022","journal-title":"Ageing Res. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0165","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13024-020-00376-6","article-title":"Mitochondria dysfunction in the pathogenesis of Alzheimer\u2019s disease: recent advances","volume":"15","author":"Wang","year":"2020","journal-title":"Mol. Neurodegener."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0170","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1474-4422(10)70277-5","article-title":"Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer\u2019s disease [published correction appears in lancet Neurol. 2011 Feb;10(2):115]","volume":"10","author":"Kapogiannis","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bioorg.2026.110044_bb0175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1478-811X-12-23","article-title":"Signaling pathway cross talk in Alzheimer\u2019s disease","volume":"12","author":"Godoy","year":"2014","journal-title":"Cell Commun. Signal"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/alzrt74","article-title":"Mitochondrial dysfunction - the beginning of the end in Alzheimer\u2019s disease? Separate and synergistic modes of tau and amyloid-\u03b2 toxicity","volume":"3","author":"Eckert","year":"2011","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.bioorg.2026.110044_bb0185","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/509654","article-title":"Mitochondrial dysfunction contributes to the pathogenesis of Alzheimer\u2019s disease","volume":"2015","author":"Cabezas-Opazo","year":"2015","journal-title":"Oxidative Med. Cell. Longev."},{"issue":"Pt 2","key":"10.1016\/j.bioorg.2026.110044_bb0190","article-title":"A\u03b2-binding with alcohol dehydrogenase drives Alzheimer\u2019s disease pathogenesis: a review","volume":"264","author":"Ye","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioorg.2026.110044_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.617588","article-title":"Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease","volume":"13","author":"Misrani","year":"2021","journal-title":"Front. Aging Neurosci."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0200","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1007\/s12035-016-9839-9","article-title":"Resveratrol and Alzheimer\u2019s disease: mechanistic insights","volume":"54","author":"Ahmed","year":"2017","journal-title":"Mol. Neurobiol."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110044_bb0205","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1002\/jcb.26097","article-title":"Mechanism of generation of oxidative stress and pathophysiology of type 2 diabetes mellitus: how are they interlinked?","volume":"118","author":"Rehman","year":"2017","journal-title":"J. Cell. Biochem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110044_bb0210","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.freeradbiomed.2010.12.005","article-title":"Oxidative stress and the etiology of insulin resistance and type 2 diabetes","volume":"51","author":"Henriksen","year":"2011","journal-title":"Free Radic. Biol. Med."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110044_bb0215","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s11011-021-00762-z","article-title":"The potential role of Keap1-Nrf2 pathway in the pathogenesis of Alzheimer\u2019s disease, type 2 diabetes, and type 2 diabetes-related Alzheimer\u2019s disease","volume":"36","author":"He","year":"2021","journal-title":"Metab. Brain Dis."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110044_bb0220","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1042\/BCJ20160503C","article-title":"Molecular mechanisms of ROS production and oxidative stress in diabetes","volume":"473","author":"Newsholme","year":"2016","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0225","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/biom5010194","article-title":"Advanced glycation end products and oxidative stress in type 2 diabetes mellitus","volume":"5","author":"Nowotny","year":"2015","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110044_bb0230","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","article-title":"Oxidative stress and diabetic complications","volume":"107","author":"Giacco","year":"2010","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0235","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1210\/er.2016-1122","article-title":"Emerging roles for MicroRNAs in diabetic microvascular disease: novel targets for therapy","volume":"38","author":"Zhang","year":"2017","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0240","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.tem.2013.08.002","article-title":"Unlocking the biology of RAGE in diabetic microvascular complications","volume":"25","author":"Manigrasso","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0245","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.diabet.2015.01.006","article-title":"Linking RAGE and Nox in diabetic micro- and macrovascular complications","volume":"41","author":"Koulis","year":"2015","journal-title":"Diabetes Metab."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110044_bb0250","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1042\/CS20160823","article-title":"Kidney, heart and brain: three organs targeted by ageing and glycation","volume":"131","author":"Frimat","year":"2017","journal-title":"Clin. Sci. (Lond.)"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0255","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/ATVBAHA.117.307263","volume":"37","author":"Schmidt","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0260","article-title":"Pharmacologic approaches against advanced glycation end products (AGEs) in diabetic cardiovascular disease","volume":"4","author":"Nenna","year":"2015","journal-title":"Res. Cardiovasc. Med."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110044_bb0265","doi-asserted-by":"crossref","first-page":"H1130","DOI":"10.1152\/ajpheart.00123.2014","article-title":"Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats","volume":"309","author":"Wang","year":"2015","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110044_bb0270","doi-asserted-by":"crossref","first-page":"887","DOI":"10.3233\/JAD-180413","article-title":"Role of the glyoxalase system in Alzheimer\u2019s disease","volume":"66","author":"Jiang","year":"2018","journal-title":"J. Alzheimer\u2019s Dis"},{"key":"10.1016\/j.bioorg.2026.110044_bb0275","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fcvm.2018.00117","article-title":"Dicarbonyl stress and Glyoxalase-1 in skeletal muscle: implications for insulin resistance and type 2 diabetes","volume":"5","author":"Mey","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0280","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s12017-012-8191-0","article-title":"Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation","volume":"14","author":"Li","year":"2012","journal-title":"NeuroMolecular Med."},{"issue":"22","key":"10.1016\/j.bioorg.2026.110044_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212335","article-title":"The mechanistic link between tau-driven Proteotoxic stress and cellular senescence in Alzheimer\u2019s disease","volume":"25","author":"Tangavelou","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0290","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1017\/cjn.2015.398","article-title":"N\u03b5-(carboxymethyl)-lysine, white matter, and cognitive function in diabetes patients","volume":"43","author":"Zhang","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110044_bb0295","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.neurobiolaging.2011.02.003","article-title":"AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation","volume":"33","author":"Li","year":"2012","journal-title":"Neurobiol. Aging"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110044_bb0300","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/a-2015-8041","article-title":"Receptor for advanced glycation end products: dementia and cognitive impairment","volume":"73","author":"Singh","year":"2023","journal-title":"Drug Res (Stuttg)."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110044_bb0305","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.neurobiolaging.2009.04.016","article-title":"Advanced glycation endproducts and their receptor RAGE in Alzheimer\u2019s disease","volume":"32","author":"Srikanth","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bioorg.2026.110044_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1120416","article-title":"Amyloid oligomers as on-pathway precursors or off-pathway competitors of fibrils","volume":"10","author":"Muschol","year":"2023","journal-title":"Front. Mol. Biosci."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110044_bb0315","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.febslet.2013.01.017","article-title":"Mechanisms of islet amyloidosis toxicity in type 2 diabetes","volume":"587","author":"Abedini","year":"2013","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0320","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/13506129.2024.2405948","article-title":"Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee","volume":"31","author":"Buxbaum","year":"2024","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0325","article-title":"IAPP toxicity activates HIF1\u03b1\/PFKFB3 signaling delaying \u03b2-cell loss at the expense of \u03b2-cell function [published correction appears in Nat Commun. 2019 Jul 31;10(1):3507. doi:10.1038\/s41467-019-11516-y.]","volume":"10","author":"Montemurro","year":"2019","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110044_bb0330","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1172\/JCI137556","article-title":"Hypoxia-inducible factors and diabetes","volume":"130","author":"Gunton","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0335","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41574-018-0096-z","article-title":"The role of hypoxia-inducible factors in metabolic diseases","volume":"15","author":"Gonzalez","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110044_bb0340","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1093\/brain\/awac181","article-title":"Autosomal dominant and sporadic late onset Alzheimer\u2019s disease share a common in vivo pathophysiology","volume":"145","author":"Morris","year":"2022","journal-title":"Brain"},{"issue":"17","key":"10.1016\/j.bioorg.2026.110044_bb0345","doi-asserted-by":"crossref","first-page":"9207","DOI":"10.3390\/ijms22179207","article-title":"Tau Protein Interaction Partners and Their Roles in Alzheimer\u2019s Disease and Other Tauopathies","volume":"22","author":"Sinsky","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0350","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13195-022-00996-8","article-title":"Glucose metabolism and AD: evidence for a potential diabetes type 3","volume":"14","author":"Gonz\u00e1lez","year":"2022","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"6340","key":"10.1016\/j.bioorg.2026.110044_bb0355","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal3321","article-title":"A subcellular map of the human proteome","volume":"356","author":"Thul","year":"2017","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110044_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1011462","article-title":"The RNA-dependent association of phosphatidylinositol 4,5-bisphosphate with intrinsically disordered proteins contribute to nuclear compartmentalization","volume":"20","author":"Sztacho","year":"2024","journal-title":"PLoS Genet."},{"key":"10.1016\/j.bioorg.2026.110044_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ceb.2023.102175","article-title":"Genome-wide tracing to decipher nuclear organization","volume":"82","author":"Flores","year":"2023","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.bioorg.2026.110044_bb0370","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fncel.2020.00016","article-title":"Cellular senescence in neurodegenerative diseases","volume":"14","author":"Mart\u00ednez-Cu\u00e9","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.bioorg.2026.110044_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172553","article-title":"Endoplasmic reticulum stress: a master regulator of metabolic syndrome","volume":"860","author":"Mohan","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0380","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s10020-024-00808-9","article-title":"Endoplasmic reticulum stress and therapeutic strategies in metabolic, neurodegenerative diseases and cancer","volume":"30","author":"Yuan","year":"2024","journal-title":"Mol. Med."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110044_bb0385","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/febs.14332","article-title":"Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer\u2019s disease","volume":"285","author":"Gerakis","year":"2018","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0390","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(12)70238-7","article-title":"Endoplasmic reticulum dysfunction in neurological disease","volume":"12","author":"Roussel","year":"2013","journal-title":"Lancet Neurol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110044_bb0395","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a033928","article-title":"Chaperoning Endoplasmic Reticulum-Associated Degradation (ERAD) and Protein Conformational Diseases","volume":"11","author":"Needham","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110044_bb0400","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1083\/jcb.201312042","article-title":"Quality control: ER-associated degradation: protein quality control and beyond","volume":"204","author":"Ruggiano","year":"2014","journal-title":"J. Cell Biol."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110044_bb0405","doi-asserted-by":"crossref","first-page":"15134","DOI":"10.18632\/aging.103612","article-title":"Signatures of cell stress and altered bioenergetics in skin fibroblasts from patients with multiple sclerosis","volume":"12","author":"Wilkins","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.bioorg.2026.110044_bb0410","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fnins.2018.00037","article-title":"Challenges for Alzheimer\u2019s disease therapy: insights from novel mechanisms beyond memory defects","volume":"12","author":"Frozza","year":"2018","journal-title":"Front. Neurosci."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110044_bb0415","first-page":"C582","article-title":"Cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. 1. An overview","volume":"307","author":"Dufey","year":"2014","journal-title":"Am. J. Phys. Cell Phys."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110044_bb0420","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nrneurol.2017.99","article-title":"ER stress and the unfolded protein response in neurodegeneration","volume":"13","author":"Hetz","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.bioorg.2026.110044_bb0425","article-title":"Exploring proinsulin proteostasis: insights into beta cell health and diabetes","volume":"12","author":"Zavarzadeh","year":"2025","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0430","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13024-025-00811-6","article-title":"The integrated stress response in neurodegenerative diseases","volume":"20","author":"Bravo-Jimenez","year":"2025","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0435","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12070-3","article-title":"Constitutive XBP-1s-mediated activation of the endoplasmic reticulum unfolded protein response protects against pathological tau","volume":"10","author":"Waldherr","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0440","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuron.2011.06.031","article-title":"Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration","volume":"71","author":"Saxena","year":"2011","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0445","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2353\/ajpath.2009.080814","article-title":"The unfolded protein response is activated in pretangle neurons in Alzheimer\u2019s disease hippocampus","volume":"174","author":"Hoozemans","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bioorg.2026.110044_bb0450","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.neurobiolaging.2016.02.005","article-title":"Repression of the eIF2\u03b1 kinase PERK alleviates mGluR-LTD impairments in a mouse model of Alzheimer\u2019s disease","volume":"41","author":"Yang","year":"2016","journal-title":"Neurobiol. Aging"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110044_bb0455","doi-asserted-by":"crossref","DOI":"10.1530\/JME-23-0066","article-title":"Vascular endothelial mineralocorticoid receptors and epithelial sodium channels in metabolic syndrome and related cardiovascular disease","volume":"71","author":"Jia","year":"2023","journal-title":"J. Mol. Endocrinol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0460","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/ijms25020804","article-title":"Diabetic vasculopathy: molecular mechanisms and clinical insights","volume":"25","author":"Jia","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.bioorg.2026.110044_bb0465","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216288","article-title":"Blood-Brain Barrier Breakdown in Alzheimer\u2019s Disease: Mechanisms and Targeted Strategies","volume":"24","author":"Alkhalifa","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110044_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108119","article-title":"Blood-brain barrier leakage in Alzheimer\u2019s disease: from discovery to clinical relevance","volume":"234","author":"Nehra","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.110044_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114517","article-title":"Opportunities and challenges in delivering biologics for Alzheimer\u2019s disease by low-intensity ultrasound","volume":"189","author":"Chen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110044_bb0480","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1084\/jem.20171406","article-title":"Alzheimer\u2019s disease: a matter of blood-brain barrier dysfunction?","volume":"214","author":"Montagne","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bioorg.2026.110044_bb0485","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.addr.2018.04.009","article-title":"Impact of aging, Alzheimer\u2019s disease and Parkinson\u2019s disease on the blood-brain barrier transport of therapeutics","volume":"135","author":"Pan","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110044_bb0490","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrn3114","article-title":"Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders","volume":"12","author":"Zlokovic","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110044_bb0495","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2337\/dc14-0396","article-title":"\u03b2-Cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment","volume":"37","author":"Halban","year":"2014","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110044_bb0500","doi-asserted-by":"crossref","first-page":"850","DOI":"10.4239\/wjd.v6.i6.850","article-title":"Diabetes mellitus: the epidemic of the century","volume":"6","author":"Kharroubi","year":"2015","journal-title":"World J. Diabetes"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0505","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4103\/2230-8210.183480","article-title":"Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum?","volume":"20","author":"Chawla","year":"2016","journal-title":"Indian J Endocrinol Metab."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110044_bb0510","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.jdiacomp.2017.08.005","article-title":"A comprehensive review of the FDA-approved labels of diabetes drugs: indications, safety, and emerging cardiovascular safety data","volume":"31","author":"Gourgari","year":"2017","journal-title":"J. Diabetes Complicat."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110044_bb0515","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/molecules25081987","article-title":"Type 2 diabetes mellitus: a review of multi-target drugs","volume":"25","author":"Artasensi","year":"2020","journal-title":"Molecules"},{"issue":"15","key":"10.1016\/j.bioorg.2026.110044_bb0520","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of Verubecestat for prodromal Alzheimer\u2019s disease","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.bioorg.2026.110044_bb0525","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of Verubecestat for mild-to-moderate Alzheimer\u2019s disease","volume":"378","author":"Egan","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0530","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13195-019-0520-1","article-title":"Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer\u2019s disease","volume":"11","author":"Egan","year":"2019","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.bioorg.2026.110044_bb0535","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fphar.2020.00279","article-title":"Pathways connecting late-life depression and dementia","volume":"11","author":"Linnemann","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110044_bb0540","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1007\/s11033-020-05693-z","article-title":"An update on potential links between type 2 diabetes mellitus and Alzheimer\u2019s disease","volume":"47","author":"De Sousa","year":"2020","journal-title":"Mol. Biol. Rep."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110044_bb0545","doi-asserted-by":"crossref","first-page":"418","DOI":"10.5603\/PJNNS.a2021.0056","article-title":"Alzheimer\u2019s disease and type 2 diabetes mellitus: similarities in pathomechanisms lead to therapeutic opportunities","volume":"55","author":"Bednarz","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0550","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110044_bb0555","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/kjm2.12800","article-title":"Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies","volume":"40","author":"Chong","year":"2024","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110044_bb0560","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0565","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WAD.0000000000000202","article-title":"Effects of the insulin sensitizer metformin in Alzheimer disease: pilot data from a randomized placebo-controlled crossover study","volume":"31","author":"Koenig","year":"2017","journal-title":"Alzheimer Dis. Assoc. Disord."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0570","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.yexcr.2016.08.013","article-title":"Metformin activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against amyloid-beta-induced mitochondrial dysfunction","volume":"347","author":"Chiang","year":"2016","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0575","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JAD-150493","article-title":"Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial","volume":"51","author":"Luchsinger","year":"2016","journal-title":"J. Alzheimer\u2019s Dis"},{"key":"10.1016\/j.bioorg.2026.110044_bb0580","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7208429","article-title":"The effect of diabetes medication on cognitive function: evidence from the PATH through life study","volume":"2016","author":"Herath","year":"2016","journal-title":"Biomed. Res. Int."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110044_bb0585","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2337\/dc13-0229","article-title":"Increased risk of cognitive impairment in patients with diabetes is associated with metformin [published correction appears in diabetes care. 2013 Nov;36(11):3850]","volume":"36","author":"Moore","year":"2013","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110044_bb0590","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1532-5415.2012.03916.x","article-title":"Metformin, other antidiabetic drugs, and risk of Alzheimer\u2019s disease: a population-based case-control study","volume":"60","author":"Imfeld","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0595","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s12035-026-05761-8","article-title":"Metformin restores innate fear deficits in young adult female APP\/PS1 mice via basolateral amygdala activation","volume":"63","author":"Zhang","year":"2026","journal-title":"Mol. Neurobiol."},{"issue":"18","key":"10.1016\/j.bioorg.2026.110044_bb0600","first-page":"8795","article-title":"Metformin activates AMPK and mTOR to inhibit RANKL-stimulated osteoclast formation","volume":"27","author":"Kim","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2026.110044_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2025.119425","article-title":"Beneficial effects of the herbal medicine zuo gui wan in a mice model of Alzheimer\u2019s disease via Drp1-mediated inhibition of mitochondrial fission and activation of AMPK\/PGC-1\u03b1-regulated mitochondrial bioenergetics","volume":"342","author":"Yan","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bioorg.2026.110044_bb0610","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.728315","article-title":"Deciphering the roles of metformin in Alzheimer\u2019s disease: a snapshot","volume":"12","author":"Liao","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0615","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282205","article-title":"The modifier effect of physical activity, body mass index, and age on the association of metformin and chronic back pain: a cross-sectional analysis of 21,899 participants from the UK biobank","volume":"18","author":"Carvalho-E-Silva","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.110044_bb0620","doi-asserted-by":"crossref","unstructured":"Battelino T, Bergenstal RM, Rodr\u00edguez A, Fern\u00e1ndez Land\u00f3 L, Bray R, Tong Z, Brown K. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):407\u2013417. doi:https:\/\/doi.org\/10.1016\/S2213-8587(22)00077-8. Epub 2022 Apr 22. Erratum in: Lancet Diabetes Endocrinol. 2022 Aug;10(8):e8. doi:10.1016\/S2213-8587(22)00169-3.","DOI":"10.1016\/S2213-8587(22)00077-8"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110044_bb0625","doi-asserted-by":"crossref","first-page":"916","DOI":"10.4239\/wjd.v12.i7.916","article-title":"Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind","volume":"12","author":"Infante","year":"2021","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.bioorg.2026.110044_bb0630","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fncel.2020.00170","article-title":"Metformin ameliorates synaptic defects in a mouse model of AD by inhibiting Cdk5 activity","volume":"14","author":"Wang","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.bioorg.2026.110044_bb0635","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/bs.podrm.2017.02.003","article-title":"Gliclazide","volume":"42","author":"Al-Omary","year":"2017","journal-title":"Profiles Drug Subst Excip Relat Methodol."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110044_bb0640","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.2337\/db15-1737","article-title":"Cerebrovascular safety of sulfonylureas: the role of KATP channels in neuroprotection and the risk of stroke in patients with type 2 diabetes","volume":"65","author":"Liu","year":"2016","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110044_bb0645","doi-asserted-by":"crossref","first-page":"10138","DOI":"10.1002\/jcp.27680","article-title":"Sulfonyl(thio)urea derivative induction of insulin secretion is mediated by potassium, calcium, and sodium channel signal transduction","volume":"234","author":"Sulis","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bioorg.2026.110044_bb0650","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.brainresbull.2018.01.001","article-title":"ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression- and anxiety-related symptoms in a rat model of Alzheimer\u2019s disease","volume":"137","author":"Esmaeili","year":"2018","journal-title":"Brain Res. Bull."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110044_bb0655","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3233\/JAD-2011-101524","article-title":"Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin","volume":"24","author":"Hsu","year":"2011","journal-title":"J. Alzheimer\u2019s Dis"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110044_bb0660","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3390\/biomedicines11112935","article-title":"The Association between Metformin Use and Risk of Developing Severe Dementia among AD Patients with Type 2 Diabetes","volume":"11","author":"Xue","year":"2023","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110044_bb0665","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11892-013-0378-8","article-title":"The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus","volume":"13","author":"Yau","year":"2013","journal-title":"Curr. Diab. Rep."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110044_bb0670","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210106","article-title":"Long-term pioglitazone treatment has no significant impact on microglial activation and tau pathology in P301S mice","volume":"24","author":"Kunze","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110044_bb0675","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fnagi.2019.00178","article-title":"Pioglitazone reduces \u03b2 amyloid levels via inhibition of PPAR\u03b3 phosphorylation in a neuronal model of Alzheimer\u2019s disease","volume":"11","author":"Quan","year":"2019","journal-title":"Front. Aging Neurosci."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110044_bb0680","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/j.1532-5415.2010.02841.x","article-title":"The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer\u2019s disease","volume":"58","author":"Hanyu","year":"2010","journal-title":"J. Am. Geriatr. Soc."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0685","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trci.2016.11.002","article-title":"Combination treatment with leptin and pioglitazone in a mouse model of Alzheimer\u2019s disease","volume":"3","author":"Fernandez-Martos","year":"2016","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.bioorg.2026.110044_bb0690","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.trci.2019.05.004","article-title":"Effects of pioglitazone on mnemonic hippocampal function: a blood oxygen level-dependent functional magnetic resonance imaging study in elderly adults","volume":"5","author":"Knodt","year":"2019","journal-title":"Alzheimers Dement (N Y)."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0695","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1532-5415.2009.02067.x","article-title":"Pioglitazone improved cognition in a pilot study on patients with Alzheimer\u2019s disease and mild cognitive impairment with diabetes mellitus","volume":"57","author":"Hanyu","year":"2009","journal-title":"J. Am. Geriatr. Soc."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0700","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20170862","article-title":"Insulin degrading enzyme contributes to the pathology in a mixed model of type 2 diabetes and Alzheimer\u2019s disease: possible mechanisms of IDE in T2D and AD","volume":"38","author":"Li","year":"2018","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.bioorg.2026.110044_bb0705","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neulet.2014.06.010","article-title":"Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers via inhibition of inflammatory responses","volume":"578","author":"Xu","year":"2014","journal-title":"Neurosci. Lett."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110044_bb0710","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1345\/aph.1Q238","article-title":"Rosiglitazone and pioglitazone for the treatment of Alzheimer\u2019s disease","volume":"45","author":"Miller","year":"2011","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0715","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild-to-moderate Alzheimer\u2019s disease: results from a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Gold","year":"2010","journal-title":"Dement. Geriatr. Cogn. Disord."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0720","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3233\/JAD-2010-100939","article-title":"A multi-center randomized proof-of-concept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer\u2019s disease","volume":"22","author":"Tzimopoulou","year":"2010","journal-title":"J. Alzheimer\u2019s Dis"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0725","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12987-022-00336-w","article-title":"Effects of fasudil on blood-brain barrier integrity","volume":"19","author":"Sato","year":"2022","journal-title":"Fluids Barriers CNS."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110044_bb0730","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1248\/bpb.b17-00929","article-title":"Apolipoprotein E gene polymorphisms affect the efficacy of Thiazolidinediones for Alzheimer\u2019s disease: a systematic review and Meta-analysis","volume":"41","author":"Iketani","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bioorg.2026.110044_bb0735","doi-asserted-by":"crossref","unstructured":"Basutkar RS, Sudarsan P, Robin SM, Bhaskar V, Viswanathan B, Sivasankaran P. Drug repositioning of pioglitazone in management and improving the cognitive function among the patients with mild to moderate Alzheimer's disease: a systematic review and meta-analysis. Neurol. India 2023;71(6):1132-1141. doi:https:\/\/doi.org\/10.4103\/0028-3886.391397.","DOI":"10.4103\/0028-3886.391397"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110044_bb0740","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","article-title":"Glucagon-like peptide 1 in health and disease","volume":"14","author":"Andersen","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"17","key":"10.1016\/j.bioorg.2026.110044_bb0745","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.3390\/ijms20174092","article-title":"The effects of dual GLP-1\/GIP receptor agonism on glucagon secretion-A review","volume":"20","author":"Mathiesen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110044_bb0750","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3389\/fimmu.2015.00386","article-title":"DPP4 in Diabetes","volume":"6","author":"R\u00f6hrborn","year":"2015","journal-title":"Front. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.bioorg.2026.110044_bb0755","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0760","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.metabol.2013.09.010","article-title":"Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells","volume":"63","author":"Lee","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.bioorg.2026.110044_bb0765","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.mce.2018.01.019","article-title":"DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes","volume":"473","author":"Bugliani","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0770","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10238-018-0519-0","article-title":"Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes","volume":"18","author":"Wang","year":"2018","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.bioorg.2026.110044_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173272","article-title":"The potential DPP-4 inhibitors from Xiao-Ke-an improve the glucolipid metabolism via the activation of AKT\/GSK-3\u03b2 pathway","volume":"882","author":"Jiang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110044_bb0780","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0785","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110044_bb0790","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/dom.13125","article-title":"Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials","volume":"20","author":"Davies","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bioorg.2026.110044_bb0795","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: current advancements & challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110044_bb0800","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.13955","article-title":"Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk","volume":"22","author":"Husain","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110044_bb0805","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110044_bb0810","doi-asserted-by":"crossref","first-page":"689","DOI":"10.4103\/ijem.IJEM_104_18","article-title":"A review on cardiovascular outcome studies of dipeptidyl Peptidase-4 inhibitors","volume":"22","author":"Khalse","year":"2018","journal-title":"Indian J Endocrinol Metab."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0815","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jjcc.2018.07.004","article-title":"Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk","volume":"73","author":"Sano","year":"2019","journal-title":"J. Cardiol."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110044_bb0820","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1007\/s12035-016-0125-7","article-title":"Linagliptin, a dipeptidyl Peptidase-4 inhibitor, mitigates cognitive deficits and pathology in the 3xTg-AD mouse model of Alzheimer\u2019s disease","volume":"54","author":"Kosaraju","year":"2017","journal-title":"Mol. Neurobiol."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110044_bb0825","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/cns.12404","article-title":"DPP-4 inhibitor Linagliptin attenuates a\u03b2-induced cytotoxicity through activation of AMPK in neuronal cells","volume":"21","author":"Kornelius","year":"2015","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.bioorg.2026.110044_bb0830","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.diabres.2016.12.010","article-title":"The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer\u2019s disease","volume":"123","author":"Isik","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0835","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00702-014-1294-z","article-title":"Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice","volume":"122","author":"Yu","year":"2015","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110044_bb0840","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/alz.12161","article-title":"Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer\u2019s disease, and the role APOE carrier status","volume":"16","author":"Wu","year":"2020","journal-title":"Alzheimers Dement."},{"issue":"Pt A","key":"10.1016\/j.bioorg.2026.110044_bb0845","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.neuropharm.2013.08.005","article-title":"Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP\/PS1 mice, a model of Alzheimer\u2019s disease","volume":"76","author":"McClean","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bioorg.2026.110044_bb0850","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bbr.2015.07.024","article-title":"Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP\/PS1 mice","volume":"293","author":"McClean","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bioorg.2026.110044_bb0855","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104896","article-title":"Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions","volume":"142","author":"Bhalla","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0860","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2023.2292461","article-title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"12","author":"Rhea","year":"2024","journal-title":"Tissue Barriers."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0865","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3233\/JAD-180433","article-title":"Neuroprotective effects of amylin analogues on Alzheimer\u2019s disease pathogenesis and cognition","volume":"66","author":"Grizzanti","year":"2018","journal-title":"J. Alzheimer\u2019s Dis"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110044_bb0870","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/mp.2014.17","article-title":"Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer\u2019s disease","volume":"20","author":"Zhu","year":"2015","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110044_bb0875","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.trci.2016.11.005","article-title":"Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer\u2019s disease","volume":"3","author":"Soudy","year":"2016","journal-title":"Alzheimers Dement (N Y)."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110044_bb0880","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2023.2292461","article-title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"12","author":"Rhea","year":"2024","journal-title":"Tissue Barriers"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:39:06Z","timestamp":1787675946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826005808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":176,"alternative-id":["S0045206826005808"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110044","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shared pathophysiology and therapeutic repurposing in Alzheimer's disease and type 2 diabetes: a critical review of convergent mechanisms and clinical challenges","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110044"}}